Clinical trial
Cetuximab, Radiotherapy and Twice Weekly Gemcitabine to Treat Pancreatic Cancer
NCT00225784 · Dartmouth-Hitchcock Medical Center, Other · Completed
Key facts
| NCT number | NCT00225784 |
|---|---|
| Title | Cetuximab, Radiotherapy and Twice Weekly Gemcitabine to Treat Pancreatic Cancer |
| Official title | A Phase II Trial of Cetuximab, Radiotherapy and Twice Weekly Gemcitabine in Patients With Adenocarcinoma of the Pancreas |
| Lead sponsor | Dartmouth-Hitchcock Medical Center, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Drug, Procedure |
| Interventions | Cetuximab/Gemcitabine, Radiotherapy |
| Enrollment | 37 |
| Start date | Feb 1, 2005 |
| Primary completion | Feb 1, 2010 |
| Completion | Sep 1, 2012 |
| First posted | Sep 26, 2005 |
| Last update posted | Jul 16, 2014 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: